Phase 2 Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People between the ages of 55 and 85
• People who are fluent in English or Spanish
• People who are willing to be randomly assigned to either the study drug (10 mg Senicapoc) or a placebo, with a higher chance of receiving the active drug
• People who have a Clinical Dementia Rating (CDR) score of 0.5 or 1, which reflects mild memory or thinking difficulties (confirm with trial site)
• People whose score on a memory and thinking test called the MoCA falls between 12 and 28, adjusted for their level of education, at the first screening visit
• People who have been diagnosed with either mild memory-related cognitive impairment (amnestic MCI) or mild Alzheimer's disease dementia, confirmed through a specialist review process
• People who have vision of at least 20/50 (with or without glasses or contact lenses) for seeing things at a distance
• People who have a "study partner" — such as a family member or close friend — who spends at least 6 hours per week with them and can help answer questions on their behalf during the trial
• Women of childbearing potential who agree to use a highly effective form of contraception throughout the trial, up to the Week 78 follow-up visit

Who may not be able to join:

• People with unstable liver problems (such as abnormal liver enzyme levels or low albumin linked to liver disease) or significant kidney disease (confirm with trial site for specific thresholds)
• People with unstable heart disease, breathing failure, moderate to severe heart failure, active cancer, unstable blood disorders, or a life expectancy of less than 3 years
• People currently using experimental treatments for Alzheimer's disease
• People who are unable to have an MRI scan, for example due to a pacemaker, certain metal implants, or severe fear of enclosed spaces
• People with a long-term psychiatric condition such as schizophrenia, a major depressive episode within the past 2 years, a current depression score above 6 on a standard scale, or any recent suicidal thoughts or attempts — though people with bipolar disorder who have been clinically stable for at least 3 years before screening may still be considered (confirm with trial site)
• People with a history of serious brain infections (such as neurosyphilis, meningitis, or encephalitis) or head injuries that caused lasting thinking or memory problems
• People with a history of alcohol or drug misuse or dependence within the past 5 years
• People with a known allergy to chemically related compounds, such as clotrimazole
• People without suitable vein access for repeated blood draws
• People who regularly use certain medications that affect the brain, including benzodiazepines, antipsychotics, opioid pain medications, or anti-epileptic drugs — though some exceptions may be considered by the lead researcher; stable doses of cholinesterase inhibitors, memantine, or antidepressants are generally permitted
• Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
• People who are unable to swallow tablets

Additional exclusions for the spinal fluid (CSF) sub-study only:

• People who have an implanted device to drain spinal fluid, or an implanted catheter in the brain or spine
• People with a history of bleeding disorders or problems with blood clotting
• People who have used blood-thinning medications (such as warfarin, heparin, dabigatran, rivaroxaban, or apixaban) within 14 days of the spinal fluid collection procedure
• People who require daily antiplatelet medications (such as aspirin above 81 mg/day, clopidogrel, or others), unless those medications can safely be paused for 7 days beforehand, as determined by the person's own doctor and the study lead
• People who have taken antiplatelet medications intermittently but used a dose within 48 hours of the procedure, or more than two doses within 7 days before it
• People with a platelet count below the normal range (some lower counts may still be acceptable — confirm with trial site)
• People with certain abnormal blood clotting test results within 14 days of the procedure (confirm with trial site for specific thresholds)

Additional exclusions for the PET scan sub-study only:

• People without suitable vein access for repeated blood draws
• People who have had more than 2 rem of radiation exposure in total over the past 12 months (confirm with trial site)
• People diagnosed with probable Alzheimer's dementia whose PET scan shows a brain amyloid measurement below a specific threshold (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.